LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Potential Markers Discovered for Severity of Childhood Arthritis

By LabMedica International staff writers
Posted on 23 Jul 2013
Researchers have discovered potential markers for the severity of the childhood arthritis. Confirmation of these biomarkers could not only change how childhood arthritis is treated, but also reduce the physical, emotional, and financial burden of the disease.

The early results of a new study of 115 children with juvenile arthritis have shown that changes in the levels of molecules formed from essential fatty acids, known as prostanoids, in the blood of these patients may predict the course of arthritis more accurately, and help provide more individualized treatment.

Dr. Christina Boros, senior lecturer in the University of Adelaide's School of Pediatrics and Reproductive Health (Adelaide, SA, Australia), and leader of the study, said, "Juvenile idiopathic arthritis can present at any age, with some children diagnosed as early as 6-9 months. The longer children go without treatment, the more likely they are to have permanent joint damage."

"For many children arthritis can be a physically debilitating and emotionally challenging condition. Some are unable to perform simple tasks because the swelling of their joints can affect their motor skills. Many children with arthritis also suffer from the psychological consequences of having a chronic disease, which can continue with them into adult life."

So far, the researchers have been able to determine relationships between the blood levels of prostanoids and disease activity in childhood arthritis. These appear to be more accurate than traditional blood markers of inflammation.

Dr Boros commented, "Arthritis in children is almost as common as juvenile diabetes, with up to one in 500 children affected. Despite having many available treatments, not all children with arthritis will respond to standard therapies."

Related Links:

University of Adelaide's School of Pediatrics and Reproductive Health




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Hematology Consumables
Bioblood Devices

Latest Clinical Chem. News

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
23 Jul 2013  |   Clinical Chem.

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
23 Jul 2013  |   Clinical Chem.

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
23 Jul 2013  |   Clinical Chem.